Artal Group’s Kyverna Therapeutics KYTX Stock Holding History

Artal Group’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-200,000	Closed	-$1.5M	–	101
2024 Q2	$1.5M	Hold	200,000	–	–	0.04%	82
2024 Q1	$4.97M	Buy	+200,000	New	+$5.58M	0.13%	64

Other funds holding KYTX

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artal Group's KYTX Position: Q3 2024 in Review

Artal Group sold out of Kyverna Therapeutics (KYTX) in Q3 2024, closing a stake of 200,000 shares — an estimated $1.5M sold.

Artal Group first reported a position in KYTX in Q1 2024 and held it in 2 quarters. The position peaked at $4.97M in Q1 2024. 94 funds tracked by Wall St. Rank hold KYTX as of Q3 2024.

Artal Group reported no remaining Kyverna Therapeutics position as of Q3 2024 after selling out during the quarter.
Artal Group sold 200,000 Kyverna Therapeutics shares in Q3 2024, an estimated $1.5M.
Artal Group first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 2 quarters.
Artal Group's Kyverna Therapeutics position peaked at $4.97M in Q1 2024.
94 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.